Noninvasive diagnosis of nasopharyngeal carcinoma: Nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA

International Journal of Cancer

Volumn 119, Issue 3, 2006, Pages 608-614

  Stevens, Servi J C ^a   Verkuijlen, Sandra A W M ^a   Hariwiyanto, Bambang ^b   Harijadi, ^b   Paramita, Dewi K ^b   Fachiroh, Jajah ^b   Adham, Marlinda ^c   Tan, I Bing ^d   Haryana, Sophia M ^b   Middeldorp, Jaap M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Carcinoma; Diagnosis; EBV; NPC; Oncogene; Viral load

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; MESSENGER RNA; PROTEIN BARF1; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; INDONESIA; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; NON INVASIVE MEASUREMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR BIOPSY; VIRUS LOAD;

ANIMALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYTODIAGNOSIS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; INDONESIA; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 33745463887     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21914     Document Type: Article

References (52)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-54.
2. IARC monographs on the evaluation of carcinogenic risks to humans volume 70: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. Lyon: IARC, 1997. 351p.
3. Spano JP, Busson P, Allan D, Bourhis J, Pignon JP, Esteban C, Armand IP. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003;39:2121-35.
4. Soeripto. Epidemiology of nasopharyngeal carcinoma. Berita Kedokteran Masyarakat 1998;XIII:207-11.
5. Devi BC, Pisani P, Tang TS, Parkin DM. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev 2004;13:482-6.
6. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970;228:1056-8.
7. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992;66:2689-97.
8. Henle G, Henle W. Epstein-Barr Virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976;17:1-7.
9. Chan KC, Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:489-96.
10. Brink AATP, Vervoort MBHJ, Middeldorp JM, Meijer CJLM, van den Brule AJC. Nucleic acid sequence-based amplification, a new method for analysis of spliced and unspliced Epstein-Barr virus latent transcripts, and its comparison with reverse transcriptase PCR. J Clin Microbiol 1998;36:3164-9.
11. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Chinese, Indonesian and European cases. J Infect Dis 2004;190:53-63.
12. Middeldorp JM, Brink AATP, van den Brule AJC, Meijer CJLM. Pathogenic role for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 2003;45:1-36.
13. Khabir A, Karray H, Rodriguez S, Rose M, Daoud J, Frikha M, Boudawara T, Middeldorp J, Jlidi R, Busson P. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J 2005;2:39.
14. Hitt MM, Allday MJ, Hara T, Karran L, Jones MD, Busson P, Tursz T, Emberg I, Griffin BE. EBV gene expression in an NPC-related tumour. EMBO J 1989;8:2639-51.
15. Hayes DP, Brink AATP, Vervoort MB, Middeldorp JM, Meijer CJ, van den Brule AJ. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol Pathol 1999;52:97-103.
16. Sall A, Caserta S, Jolicoeur P, Franqueville L, Turenne-Tessier M, Ooka T. Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein. Oncogene 2004;23:4938-44.
17. Wei MX, de Turenne-Tessier M, Decaussin G, Benet G, Ooka T. Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus. Oncogene 1997;14:3073-81.
18. Wei MX, Ooka T. A transforming function of the BARF1 gene encoded by Epstein-Barr virus. EMBO J 1989;8:2897-903.
19. de Turenne-Tessier M, Jolicoeur P, Middeldorp JM, Ooka T. Expression and analysis of the Epstein-Barr virus BARF1-encoded protein from a tetracycline-regulatable adenovirus system. Virus Res 2005;109:9-18.
20. Seto E, Yang L, Middeldorp J, Sheen TS, Chen JY, Fukayama M, Eizuru Y, Ooka T, Takada K. Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 2005;76:82-8.
21. Sall A, Caserta S, Jolicoeur P, Franqueville L, de Turenne-Tessier M, Ooka T. Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein. Oncogene 2004;23:4938-44.
22. Stevens SJC, Verkuijlen SAWM, Hariwiyanto B, Harijadi, Fachiroh J, Paramita D, Tan IB, Haryana SM, Middeldorp JM. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005;43:3066-73.
23. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003;63:2028-32.
24. Tune CE, Liavaag PG, Freeman JL, van den Brekel MW, Shpitzer T, Kerrebijn JD, Payne D, Irish JC, Ng R, Cheung RK, Dosch HM. Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst 1999;91:796-800.
25. Tong JH, Tsang RK, Lo KW, Woo JK, Kwong J, Chan MW, Chang AR, van Hasselt CA, Huang DP, To KF. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res 2002;8:2612-9.
26. Lin SY, Tsang NM, Kao SC, Hsieh YL, Chen YP, Tsai CS, Kuo TT, Hao SP, Chen IH, Hong JH. Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck 2001;23:194-200.
27. Hao SP, Tsang NM, Chang KP. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs. Cancer 2003;97:1909-13.
28. Stevens SJC, Verkuijlen SAWM, van den Brule AJC, Middeldorp JM. Comparison of quantitative competitive PCR with LC-based PCR for monitoring of Epstein-Barr virus DNA load in clinical specimens. J Clin Microbiol 2002;40:4105-13.
29. Stevens SJC, Verkuijlen SAWM, Middeldorp JM. Quantitative detection of Epstein-Barr virus DNA in clinical specimens by rapid real-time PCR targeting a highly conserved region of EBNA-1. Methods Mol Biol 2005;292:15-26.
30. Meij P, Vervoort MBHJ, Meijer CJLM, Bloemena E, Middeldorp JM. Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells. J Virol Methods 2000;90:193-204.
31. Chen MR, Middeldorp JM, Hayward SD. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol 1993;67:4875-85.
32. Sobin LH, Wittekind C, eds. UICC TNM classification of malignant tumors, 5th ed. Berlin, Germany: Springer, 1997.
33. Damen M, Sillekens P, Sjerps M, Melsert R, Frantzen I, Reesink HW, Lelie PN, Cuypers HT. Stability of hepatitis C virus RNA during specimen handling and storage prior to NASBA amplification. J Virol Methods 1998;72:175-84.
34. Bruisten SM, Oudshoorn P, van Swieten P, Boeser-Nunnink B, van Aarle P, Tondreau SP, Cuypers HT. Stability of HIV-1 RNA in blood during specimen handling and storage prior to amplification by NASBA-QT. J Virol Methods 1997;67:199-207.
35. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen P, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
36. Hesselink AT, van den Brule AJC, Groothuismink ZMA, Molano M, Berkhof J, Meijer CJLM, Snijders PJF. Comparison of three different PCR methods for quantifying HPV16 DNA in cervical scrapes. J Clin Microbiol 2005;43:4868-71.
37. Deiman B, van Aarle P, Sillekens P. Characteristics and applications of nucleic acid sequence-based amplification (NASBA). Mol Biotechnol 2000;20:163-79.
38. Stevens SJ, Brink AA, Middeldorp JM. Profiling of Epstein-Barr virus latent RNA expression in clinical specimens by gene-specific multi-primed cDNA synthesis and PCR. Methods Mol Biol 2005;292:27-38.
39. Busson P, McCoy R, Sadler R, Gilligan K, Tursz T, Raab-Traub N. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 1992;66:3257-62.
40. Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP. Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal brushing and peripheral blood of nasopharygeal carcinoma patient. Int J Cancer 2003;105:851-5.
41. Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP. Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. Clin Cancer Res 2003;9:1033-8.
42. Makitie AA, Reis PP, Zhang T, Chin SF, Gullane P, Siu LL, Kamel-Reid S, Irish J. Epstein-Barr virus DNA measured in nasopharyngeal brushings in patients with nasopharyngeal carcinoma: pilot study. J Otolaryngol 2004;33:299-303.
43. Chang AR, Liang XM, Chan AT, Chan MK, Teo PM, Johnson PJ. The use of brush cytology and directed biopsies for the detection of nasopharyngeal carcinoma and precursor lesions. Head Neck 2001;23:637-45.
44. Chen MH, Chang AR, Lo SY. The usefulness of cytodiagnosis and DNA cytometry on nasopharyngeal brush smears for the diagnosis of nasopharyngeal carcinoma. Head Neck 2002;24:223-7.
45. Sheen TS, Ko JY, Chang YL, Chang YS, Huang YT, Chang Y, Tsai CH, Hsu MM. Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. Head Neck 1998;20:732-8.
46. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
47. Laichalk LL, Hochberg D, Babcock GJ, Freeman RB, Thorley-Lawson DA. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 2002;16:745-54.
48. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, Bouguermouh A, Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 2000;60:5584-8.
49. Morrison JA, Raab-Traub N. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {β}-catenin signaling. J Virol 2005;79:2375-82.
50. Scholle F, Bendt KM, Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000;74:10681-9.
51. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
52. Brink AATP, Zielinski GD, Steenbergen RD, Snijders PJF, Meijer CJLM. Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology 2005;16:7-12.